Increased paternal age is associated with several diseases, possibly due to the age associated increase in sporadic de novo mutations in male germ cells. Several studies have reported an association between paternal age at conception and their offspring's risk of schizophrenia. If this association was due to de novo mutations one would expect to find a stronger association between paternal age and schizophrenia in cases with no family history of the disorder.

Conclusions
Our findings confirm advancing paternal age as a strong independent risk factor for schizophrenia and indicate that 15.5% of cases of schizophrenia in our cohort could be due to the patient having a father who was aged >30 years at birth. We found a stronger association in subjects without a family history of schizophrenia, supporting the hypothesis that accumulating de novo mutations in the germ lines of older fathers could play an important part in the aetiology of schizophrenia.

What is already known on this topic
Increased paternal age is associated with several diseases, possibly due to the age associated increase in sporadic de novo mutations in male germ cells. Several studies have reported an association between paternal age at conception and their offspring's risk of schizophrenia.

What this study adds
There is a strong positive association between paternal age and schizophrenia that is not due to sociodemographic, birth related, or socioeconomic factors or family history or early parental death.

Paternal age is only weakly associated with other non-schizophrenic non-affective psychosis

This association is stronger in those with no family history of schizophrenia, supporting the hypothesis that accumulating de novo mutations in the germ lines of older fathers could play an important part in the aetiology of schizophrenia.

What is already known on this topic
Increased paternal age is associated with several diseases, possibly due to the age associated increase in sporadic de novo mutations in male germ cells. Several studies have reported an association between paternal age at conception and their offspring's risk of schizophrenia. If this association was due to de novo mutations one would expect to find a stronger association between paternal age and schizophrenia in cases with no family history of the disorder.

Conclusions
Our findings confirm advancing paternal age as a strong independent risk factor for schizophrenia and indicate that 15.5% of cases of schizophrenia in our cohort could be due to the patient having a father who was aged >30 years at birth. We found a stronger association in subjects without a family history of schizophrenia, supporting the hypothesis that accumulating de novo mutations in the germ lines of older fathers could contribute to an increased risk of schizophrenia in their offspring.

In England and Wales the average paternal age has increased from 29.2 years in 1980 to 32.1 in 2002. Assuming a background annual incidence rate for schizophrenia of 10/100 000 and that the association is causal, our results suggest that the increase in paternal age since 1980 could account for 710 out of the 6633 new cases of schizophrenia diagnosed in the United Kingdom in 2002.

We thank Christina Dalman, Peter Allebeck, and Susanne Wicks for their helpful comments, Stan Zammit for his help with accessing all the relevant literature, and Geoff Adams for statistical/database support.

Contributors: See bmj.com

Funding: Stanley Medical Research Institute.

Competing interests: None declared.

Ethical approval: The ethics committee at the Karolinska Institute, Stockholm, Sweden, approved this study.

18 Dalman C, Brum J, Collberg J, Allebeck P. Young cases of schizophrenia identified in a national inpatient register—are the diagnoses valid? Sc Psychiatry Epidemiol 2002;36:527-31.

doi 10.1136/bmj.382.43.627.96.55

Corrections and clarifications
ABC of preterm birth: Immediate care of the preterm infant

A drug dosage cited in this article by Peter W Fowile and William McGuire substantially underestimated the correct dose (9 October, pp 845-8). In the box entitled “Drugs used in acute resuscitation of the preterm infant” (p 847), we correctly stated that the dosage of dextrose (in needed) is 2.5 ml/kg, but the amount of 10% dextrose to be given is in fact 250 mg/kg (not 250 µg/kg, as stated).

The PROGRESS trial three years later: time for more action, less distraction (commentary)

A misspelling of someone’s name was not picked up until after this commentary by Stephen MacMahon and colleagues had gone to press (23 October, p 970-1). In the contributors section, Jeffrey Cutler’s name was misspelled.

Second drug firm found guilty of “switching” patients to new drugs

GlaxoSmithKline (GSK) wishes to point out that, contrary to what was reported in the opening section of this news article by Zosia Kmietowicz (16 October, p 876), the Airways Integrated Management Service (AIMS) was not found in breach of the Code of Practice of the Prescription Medicines Code of Practice Authority (set up by the Association of British Pharmaceutical Industry). GSK has not been told to withdraw the service. However, as was stated later in the article in a statement from GSK, “GSK accepts that the materials used to introduce [AIMS] to practices were, although unintentionally, in breach of the Code of Practice and has agreed to withdraw these materials.” The company affirms that it has now withdrawn the materials and that it remains fully committed to the spirit and the letter of the Code of Practice.